1256 related articles for article (PubMed ID: 15791661)
21. Maternal serum screening of Palestinian women in the West Bank.
Husseini A; Akkawi M
East Mediterr Health J; 2005 Jul; 11(4):824-7. PubMed ID: 16700399
[TBL] [Abstract][Full Text] [Related]
22. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
23. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
24. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops.
Lambert-Messerlian GM; Saller DN; Tumber MB; French CA; Peterson CJ; Canick JA
Prenat Diagn; 1998 Oct; 18(10):1061-7. PubMed ID: 9826898
[TBL] [Abstract][Full Text] [Related]
25. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
[TBL] [Abstract][Full Text] [Related]
26. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
Wald NJ; Watt HC
Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
[TBL] [Abstract][Full Text] [Related]
27. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
28. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance.
Rudnicka AR; Wald NJ; Huttly W; Hackshaw AK
Prenat Diagn; 2002 Oct; 22(10):893-7. PubMed ID: 12378572
[TBL] [Abstract][Full Text] [Related]
29. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
Palomaki GE; Neveux LM; Knight GJ; Haddow JE
Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
[TBL] [Abstract][Full Text] [Related]
30. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
31. Second-trimester maternal serum analyte levels associated with fetal trisomy 13.
Saller DN; Canick JA; Blitzer MG; Palomaki GE; Schwartz S; Blakemore KJ; Haddow JE
Prenat Diagn; 1999 Sep; 19(9):813-6. PubMed ID: 10521837
[TBL] [Abstract][Full Text] [Related]
32. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
[TBL] [Abstract][Full Text] [Related]
33. [Maternal serum screening for Down syndrome and neural tube defects].
van Rijn M; Christiaens GC; van der Schouw YT; Hagenaars AM; de Pater JM; Visser GH
Ned Tijdschr Geneeskd; 1998 Feb; 142(8):409-15. PubMed ID: 9562776
[TBL] [Abstract][Full Text] [Related]
34. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
35. [Second trimester maternal serum screening for Down's syndrome in women of advanced maternal age: a multi-center prospective study].
Qi QW; Jiang YL; Liu JT; Bian XM; Li Y; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Cai Y
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):737-41. PubMed ID: 19087538
[TBL] [Abstract][Full Text] [Related]
36. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
[TBL] [Abstract][Full Text] [Related]
37. Placental protein 13 as a first trimester screening marker for aneuploidy.
Koster MP; Wortelboer EJ; Cuckle HS; Stoutenbeek P; Visser GH; Schielen PC
Prenat Diagn; 2009 Dec; 29(13):1237-41. PubMed ID: 19844942
[TBL] [Abstract][Full Text] [Related]
38. Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters.
Zhang J; Lambert-Messerlian G; Palomaki GE; Canick JA
Prenat Diagn; 2011 Jun; 31(6):583-8. PubMed ID: 21480302
[TBL] [Abstract][Full Text] [Related]
39. Are Down syndrome fetuses detected through maternal serum screening similar to those remaining undetected?
Christiaens GC; Hagenaars AM; Akkerman C; De France HF
Prenat Diagn; 1996 May; 16(5):437-42. PubMed ID: 8844002
[TBL] [Abstract][Full Text] [Related]
40. Biochemical screening for congenital defects.
Bahado-Singh RO; Sutton-Riley J
Obstet Gynecol Clin North Am; 2004 Dec; 31(4):857-72, xi. PubMed ID: 15550339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
